Press release
Regeneron Announces New Investment in Manufacturing of its Industry-Leading Biologic Medicines
New manufacturing and supply agreement with FUJIFILM Diosynth Biotechnologies in North Carolina will enable additional production of Regeneron’s biologic
About this update from Regeneron Pharmaceuticals, Inc.
[{"type":"text","content":"New manufacturing and supply agreement with FUJIFILM Diosynth Biotechnologies in North Carolina will enable additional production of Regeneron’s biologic medicines and support high-paying jobs in the region Regeneron’s ongoing and planned investments in New York and North Carolina infrastructure and manufacturing expected to total more than $7 billion TARRYTOWN, N.Y., April 22, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced a significant expansion of its manufacturing capacity through a new agreement with FUJIFILM Diosynth Biotechnologies (“Fujifilm”) to manufacture and supply bulk drug product of Regeneron’s commercial biologic medicines at their Holly Springs, North Carolina, campus. Regeneron, already one of the largest manufacturers of biologics in the world, will nearly double its U.S. large-scale manufacturing capacity by accessing Fujifilm’s new state-of-the-art biopharmaceutical facility. With technology transfer beginning immediately and a ten-year term, the total investment is estimated to exceed $3 billion. “Regeneron is an American success story, with over 80 percent of our workforce and assets in the U.S. and all of our FDA-approved medicines invented in our New York laboratories. Our innovative approach has filled our commercial and clinical pipeline with important new medicines and driven a need for even more manufacturing capacity to fulfill the promise of our science,” said Leonard Schleifer, M.D., Ph.D., Board co-Chair, President and Chief Executive Officer of Regeneron. “We are meeting this need through increased investment in New York and North Carolina. We are proud to advance biotech innovation, which directly improves the health of people around the globe, while generating economic growth and high-paying jobs for America itself.” This new investment underscores Regeneron’s commitment to deliver innovative medicines to patients. Regeneron continues to invest heavily in its New York State operations, where an approximately $3.6 billion expansion of its Tarrytown campus is underway, creating 1,000 full-time, high-skill jobs and expanding research, preclinical manufacturing and support facilities. In addition, the company is constructing a brand new, state-of-the-art fill/finish manufacturing facility in Rensselaer, New York, and has acquired an over 1 million-square fo...